Fosun Wanbang Pharma Group

Subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196) · China

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
IL-17AMonoclonal antibody
Psoriasis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 December 2025Filing acceptedRoconkibartNMPA accepts the roconkibart marketing application in plaque psoriasis
CN, NMPA · Shanghai Junshi Bioscience · Source ↗

Financial reports

No financial reports recorded.